Alnylam and Merck Amend, Consolidate RNAi Alliances | GenomeWeb

Alnylam and Merck Amend, Consolidate RNAi Alliances

Jul 06, 2006

NEW YORK (GenomeWeb News) - Alnylam Pharmaceuticals has amended its two RNAi collaboration agreements with Merck and consolidated them into a single collaboration, Alnylam said today.

The amendments focus on the nine new therapeutic targets that Merck will name at a later date. These new programs are in addition to the existing collaboration on NOGO pathway for spinal cord injury treatments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

The Apple's Journey

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

This Week in Nature

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Change Is Hard to Do

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

Possible Paths for CUP

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.